OssDsign AB
STO:OSSD
OssDsign AB
Other
OssDsign AB
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OssDsign AB
STO:OSSD
|
Other
-kr8.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Other
kr72.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
Doxa AB
STO:DOXA
|
Other
-kr30.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Other
-€500k
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OssDsign AB
Glance View
OssDsign AB is a holding company, which designs, manufactures, and sells implants and material technology for bone regeneration. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2019-05-24. The company aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The firm uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The firm's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
See Also
What is OssDsign AB's Other?
Other
-8.9m
SEK
Based on the financial report for Dec 31, 2025, OssDsign AB's Other amounts to -8.9m SEK.
What is OssDsign AB's Other growth rate?
Other CAGR 5Y
-7%
Over the last year, the Other growth was -7 536%. The average annual Other growth rates for OssDsign AB have been -34% over the past three years , -7% over the past five years .
